Your browser doesn't support javascript.
loading
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
Li, Jing-Xin; Hou, Li-Hua; Gou, Jin-Bo; Yin, Zun-Dong; Wu, Shi-Po; Wang, Fu-Zhen; Zhang, Zhe; Peng, Zhi-Hang; Zhu, Tao; Shen, Hong-Bing; Chen, Wei; Zhu, Feng-Cai.
Affiliation
  • Li JX; National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China; School of Public Health, National Vaccine Innovation Platform, Nanjing Medical University, Nanjing, Jiangsu Province, China.
  • Hou LH; Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.
  • Gou JB; Cansino Biologics, Tianjin, China.
  • Yin ZD; Chinese Center for Disease Control and Prevention, Beijing, China.
  • Wu SP; Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.
  • Wang FZ; Chinese Center for Disease Control and Prevention, Beijing, China.
  • Zhang Z; Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.
  • Peng ZH; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, China.
  • Zhu T; Cansino Biologics, Tianjin, China.
  • Shen HB; Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, China; Chinese Center for Disease Control and Prevention, Beijing, China. Electronic address: hongbingshen@njmu.edu.cn.
  • Chen W; Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China. Electronic address: cw0226@foxmail.com.
  • Zhu FC; National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China; School of Public Health, National Vaccine Innovation Platform, Nanjing Medical University, Nanjing, Jiangsu Province, China. Electronic address:
Lancet Infect Dis ; 23(10): 1143-1152, 2023 10.
Article in En | MEDLINE | ID: mdl-37352880
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 4_TD Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Lancet Infect Dis Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 4_TD Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Lancet Infect Dis Year: 2023 Document type: Article